Gender-affirming hormone therapy for transgender individuals in China
China Gender-affirming Hormone Therapy Study in Transgender Men and Women
This study is trying to understand how gender-affirming hormone therapy affects the physical and mental health of transgender individuals in China over a year.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 240 (estimated) |
| Ages | 18 Years to 40 Years |
| Sex | All |
| Sponsor | Peking University Third Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05318755 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather data on the physical and psychological effects of gender-affirming hormone therapy (GAHT) among transgender individuals in China. Participants seeking GAHT will be enrolled from a major transgender medical center and will undergo interviews and evaluations regarding their life experiences, gender identity, and health conditions. The study will follow participants for up to 12 months, assessing their mental and physical health before and during the hormone therapy. The findings aim to fill the gap in knowledge regarding transgender medical care in China.
Who should consider this trial
Good fit: Ideal candidates are transgender men and women aged 18 to 40 who wish to start GAHT and meet specific diagnostic criteria.
Not a fit: Patients with uncontrolled comorbid diseases, current psychiatric disorders, or a history of gender-affirming surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the effects of GAHT, improving care for transgender individuals in China.
How similar studies have performed: While studies on GAHT exist globally, this specific approach in the Chinese context is novel and aims to address a significant gap in local data.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Transgender men and women * Meet criteria of Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) for gender dysphoria * Aged between 18 to 40 years * People desire to start the GAHT * No previous history of gender-affirming interventions * Having full ability to make informed consent * Dextromanual Exclusion Criteria: * Disorders of sex development * Who has fertility demand but have not made fertility preservation * With contradictions of GAHT * Comorbid diseases are not under control * Alcohol or drug abuse * Hormonal and chromosomal disorders * History of gender affirming surgery * Current psychiatric disorders * History of brain trauma or neurological pathologies * Current use of medications with psychotropic effects within two weeks (antipsychotic or antiepileptic agents, lithium, benzodiazepines or opioid analgesics) * Claustrophobia * Implanted metal and medical devices (pacemakers, ceramic teeth, etc.), * Tattoos or eyebrow tattooing (heavy metal dye)
Where this trial is running
Beijing, Beijing Municipality
- Peking University Third Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Tianpei Hong, PhD., M.D. — Department of Endocrinology and Metabolism, Peking University Third Hospital
- Study coordinator: Ye Liu, PhD., M.D.
- Email: yeliumed@bjmu.edu.cn
- Phone: +86-10-82265025
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.